Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

about

Approach for Identifying Human Leukocyte Antigen (HLA)-DR Bound Peptides from Scarce Clinical Samples.Basement membranes and autoimmune diseases.

P2860

Q38756127-8DBEF375-EC7C-4CA6-9C71-101749695559 Q38920115-4C5FD671-D6E7-4551-BD9F-5B0B45D9FE20

P2860

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Item

http://www.wikidata.org/entity/Q37353611

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

@en

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

@nl

type

Item

label

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

@en

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

@nl

prefLabel

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

@en

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

@nl

P1476

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

@en

P2093

Masha Fridkis-Hareli

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Risk factors and primary prevention trials for type 1 diabetes

Structural and Functional Studies of trans -Encoded HLA-DQ2.3 (DQA1*03:01/DQB1*02:01) Protein Molecule

Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide

X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action

Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

P304

826191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1155/2013/826191

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2013-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259269034

http://www.w3.org/2001/XMLSchema#string

P698

24324511

http://www.w3.org/2001/XMLSchema#string

P921

peptide

membrane proteins

autoimmune disease

P932

3845387

http://www.w3.org/2001/XMLSchema#string

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

about

P2860

P2860

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P478

P5008

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P478

P5008

P577

P5875

P698

P921

P932